SICO SOCIETÀ ITALIANA CARBURO OSSIGENO SPA a Socio Unico has activated a pharmacovigilance system in line with the current Regulations associated with medicinal products for human use at EU level which allows us to assume full responsibility for our products and to take appropriate actions when necessary.
Pharmacovigilance is defined by the World Health Organization as “The science and activities related to the identification, evaluation, understanding and prevention of adverse reactions or any other problems related to the use of medicinal products.
In line with this general definition, the main objectives of pharmacovigilance are:
- prevention of harm from adverse reactions in humans;
- promoting the safe and effective use of medicinal products, in particular by providing timely information on their safety to patients, healthcare professionals and the general public.
Pharmacovigilance is therefore an activity that contributes to the protection of patients and public health.
What is an adverse drug reaction? It is the harmful and unwanted response to a medicinal product.
Adverse reactions may arise from an authorized or unauthorized use of the medicinal product, or from professional exposure. Conditions of unauthorized use include, among others, overdose, misuse, abuse and medication errors.
Information on how to report an adverse reaction to a medicinal gas with AIC SICO holder
If you wish to report an adverse reaction to a medicinal gas owned by AIC SICO SOCIETÀ ITALIANA CARBURO OSSIGENO SPA a Socio Unico, you can contact us at the following telephone numbers
QPPV Mobile: +39 3461524287
GB Pharma Srl landline switchboard: +39 0382.530676 / +39 0382.530059
Or by email to the following address:
We will be happy to process your request as soon as possible.
